Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Countries and organisations
Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.
Free access · No subscription for research tools or data exports
Explore registry geography and organisations
4 trials match this view; 8 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.
Enrollment sum: 519 across 4 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.
Recorded study-start years
Current indexed registry status
Reported research conditions
Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.
Countries with reported trial locations
Sponsors recorded in this index
Matching trial records
| Trial | Sponsor and phase | Status | Enrollment | Start / primary completion / completion | Research workflow |
|---|---|---|---|---|---|
| Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsOCD · Major Depressive Disorder (MDD) · Alcohol Use Disorder (AUD) · Healthy Volunteer · Migraine · PTSD · PTSD - Post Traumatic Stress Disorder · Addiction · Tobacco Use Disorder · Obsessive Compulsive Disorder (OCD) · Opioid Use Disorder | Yale University Phase not reported | Terminated Registry updated 2026-07-09 | 5 ACTUAL | 2024-12-12 2026-06-14 2026-06-14 | |
| The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.COPD (Chronic Obstructive Pulmonary Disease) · ALS (Amyotrophic Lateral Sclerosis) · MS (Multiple Sclerosis) · Major Depressive Disorder (MDD) · Atypical Parkinson Disease | University Medical Center Groningen PHASE2 | Recruiting Registry updated 2026-05-08 | 108 ESTIMATED | 2025-07-01 2027-01-01 2028-01-01 | |
| Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical TrialMajor Depressive Disorder (MDD) · Alcohol Use Disorder (AUD) | Centre for Addiction and Mental Health PHASE2 | Not yet recruiting Registry updated 2026-02-12 | 30 ESTIMATED | 2026-03 2028-03 2028-06 | |
| Retrospective Observational Study of Intensity Effects in Psychedelic-assisted TreatmentMajor Depressive Disorder (MDD) · Anxiety Disorders · Substance Use Disorder (SUD) · PTSD - Post Traumatic Stress Disorder | University Hospital, Geneva Phase not reported | Active, not recruiting Registry updated 2025-10-02 | 376 ESTIMATED | 2020-06-01 2025-04-30 2025-09-30 |
Reported research facilities
Connecticut Mental Health CenterHamden, Connecticut, United States
West Haven VA Medical CenterWest Haven, Connecticut, United States
National Institute of Mental HealthPrague, Czechia
Bispebjerg HospitalCopenhagen, Denmark
University Medical Center GroningenGroningen, Provincie Groningen, Netherlands
Champalimaud FoundationLisbon, Portugal
Centre for Addiction and Mental HealthToronto, Ontario, Canada
Geneva University HospitalGeneva, Switzerland
This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.